Use of monoclonal antibodies to detect disease associated HLA-DRB1 alleles and the shared epitope in rheumatoid arthritis

Ian Wicks, Geoff McColl, Angela D’Amico, Loretta Dougherty, Brian Tait

Abstract

Objective—To use a panel of monoclonal antibodies (Mab) which recognise HLA class II alleles associated with rheumatoid arthritis for fluorescence activated cell sorter (FACS) analysis of peripheral blood mononuclear cells (PBMC) from patients with early and established rheumatoid arthritis and to compare these results against DNA oligotyping of HLA class II molecules in the same patients.

Methods—27 patients (18 from an early arthritis clinic, nine with established rheumatoid arthritis) were studied using both techniques. PBMC were stained with Mab which recognise the shared epitope, the HLA-DRB1*04 molecule and its *0401, *0404 subtypes in the presence of bound peptide. Mab stained cells were analysed by FACS. Genomic DNA was prepared from PBMC and used for DNA oligotyping and sequencing by standard methods.

Results—FACS analysis of Mab stained PBMC gave identical results to those obtained by DNA oligotyping in 26/27 patients. The antibodies identified the shared epitope in 14/14 cases and the presence of an HLA-DRB1*04 molecule in 12/12 cases. HLA-DRB1*0404 was identified in 4/4 cases. HLA-DRB1*0401 was identified in 5/6 cases. One patient oligotyped as HLA-DRB1*0401, but consistently failed to react with the *0401 Mab. DNA sequencing of the second exon of the HLA-DRB1*0401 allele in this patient confirmed a normal HLA-DRB1*0401 genotype.

Conclusions—FACS analysis of PBMC stained with Mab recognising the shared epitope and rheumatoid arthritis associated HLA susceptibility molecules provides a rapid, reliable, and more accessible alternative to DNA oligotyping. The apparent discordance between phenotypic and genetic analysis of HLA-DRB1*0401 in one patient, may reflect variability in HLA-DRB1*0401 gene expression or in class II peptide presentation.

(Rheum Dis 1997;56:135–139)

Rheumatoid arthritis is a common but clinically heterogeneous disease. Recent work suggests that much of the joint damage in more severe cases occurs in the first few years of the disease. Accordingly, there is a trend towards earlier and more aggressive therapeutic intervention. Early stratification of patients who are at risk for severe disease is an important clinical issue for these reasons. Many studies have confirmed an association between rheumatoid arthritis and a restricted number of alleles at the highly polymorphic HLA-DRB1 locus (primarily DRB1*0401, *0404, and *0101). Each of these alleles shares sequence homology in the third hypervariable region of the β chain, which is referred to as the shared epitope. In a study of 201 patients with rheumatoid arthritis, who were unselected for disease severity, the presence of a single copy of *0401, *0404, or *0101 was associated with an odds ratio for rheumatoid arthritis of 3.5. Two identical copies of these alleles gave an odds ratio of 7.8 and this increased to 25.6 with *0401/*0404 compound heterozygosity. Similar results were obtained from an analysis of 120 patients presenting with early arthritis. In this study, 10/11 compound heterozygotes (*0401/*0404) developed erosions at one year. Conversely, patients without the HLA-DRB1 susceptibility alleles are at low (10-20%) risk for severe disease.

These molecular techniques, which are initially using serological and cellular typing reagents and more recently with molecular techniques. The standard method for determining HLA-DR and its subtypes now involves isolation of genomic DNA from peripheral blood cells, the polymerase chain reaction (PCR), with sequence specific oligonucleotide primers and dot blotting, followed by hybridisation with probes directed at hypervariable region sequence differences. These molecular techniques, which are generally carried out in the context of HLA matching for organ transplantation, require specialised expertise and equipment and stringent quality control. While HLA typing has been used as a research tool in the study of rheumatoid arthritis, it has not been generally accessible as an aid to clinical management.

Recently, monoclonal antibodies (Mab) which recognise HLA-DR4, its subtypes *0401 and *0404, and the shared epitope (QKAA/QRAA) have been generated. These antibodies are conformationally dependent...
and require peptide loading of the MHC molecule.\textsuperscript{6} Fluorescence activated cell sorter (FACS) analysis of peripheral blood cells potentially offers a faster and more accessible method for identifying patients carrying rheumatoid arthritis associated HLA-DRB1 alleles early in the course of the disease. In this study, we compared the results of FACS analysis and genotyping in 27 patients, 18 of whom came from an early inflammatory arthritis clinic and nine had established rheumatoid arthritis.

Methods

SUBJECTS

Eighteen consecutive patients, all of whom fulfilled the 1987 revised American Rheumatism Association (ARA) criteria for rheumatoid arthritis, were enrolled from a study of early inflammatory polyarthritis conducted at the Royal Melbourne Hospital (RMH). Patients came from the community of suburban Melbourne. Nine patients with established rheumatoid arthritis—drawn from the RMH outpatient rheumatology clinic—were also studied.

ANTIBODY STAINING

Peripheral blood was collected into heparinised tubes and the mononuclear cells isolated on a LeucoSep Ficol density gradient (Oropharma AG, Zurich). Peripheral blood mononuclear cells (PBMC, $2 \times 10^8$) were stained with 30 µl of irrelevant mouse immunoglobulin, Mab NFLD.D1 (anti-DR4; B1*04), Mab NFLD.D2 (anti-shared epitope QKRAA/QRRAA), Mab NFLD.D11 (anti-DR4Dw4; B1*0401), NFLD.D13 (anti-DR4Dw14; B1*0404), or NFLD.M6 (Mab to monomorphic determinant on HLA-DR; positive control) (supplied as supernatants by Terra Nova Biotech, Newfoundland, Canada). In cellular enzyme linked immunosorbent assays (ELISA), the NFLD.D2 also showed limited binding to QARAA containing alleles.\textsuperscript{7} Fluorescein isothiocyanate (FITC) conjugated Mab anti-CD3 (1:40) (Dako, Denmark) was added to all tubes in order to demarcate clearly the HLA class II expressing B cells. Cells were held for 20 minutes on ice and washed once through fetal calf serum. Phycoerythrin conjugated goat anti-mouse Mab was added (Terra Nova Biotech, Boehringer Mannheim, Germany) and cells held on ice and washed twice with fetal calf serum. Fluorescence in the FITC channel was quantified by double staining (figure). Increased B cell fluorescence in the phycoerythrin channel was usually obvious from inspection, but quadrants were set on all samples, using goat anti-mouse (GAM) conjugated phycoerythrin alone (negative control) and NFLD.M6 (positive control) to estimate staining in the phycoerythrin channel. The following formula was used to quantify fluorescence in the phycoerythrin channel:

$$\frac{\text{% Test}}{\text{% Positive control}} \times 100 - \frac{\text{% Neg control}}{\text{Negative control}}$$

A figure of greater than 20% was recorded as positive staining. FACS results were analysed without knowledge of the genotype.

HLA DNA Oligotyping

DNA was isolated using the method of Miller \textit{et al.}\textsuperscript{8} from the buffy coat of anticoagulated blood samples. Genomic DNA was amplified by the PCR, dot blotted, and probed with digoxigenin labelled (Roche, Mannheim, Germany) oligonucleotides specific for HLA-DRB1 variable sequences. A two step procedure was used, consisting of PCR amplification of the DRB1 second exon using generic primers and hybridisation with probes providing a serologically equivalent DR assignment (including DR4 and DR0101/0102). Secondly, primers amplifying only the DR4 group of alleles were used in the PCR with genomic DNA and the product probed with a series of oligonucleotides which defined *0401-*0422. A similar procedure was used to define the DR1 alleles. Following hybridisation and stringent washing, bound probes were detected using an anti-digoxigenin-alkaline phosphatase conjugate and chemiluminescent substrate (Roche, Mannheim, Germany). Hybridisation signals were visualised by exposure to x ray film (Kodak XAR-5).

HLA-DR4 I Sequencing

Primers flanking the second exon of the HLA-DR4 I gene were used to PCR amplify a 300 base pair fragment from the genomic DNA of patient 15. The PCR product was purified with a High Pure PCR product purification kit (Roche, Mannheim, Germany) and sequenced in both directions using a Taq Dye deoxy terminator cycle sequencing kit (Perkin Elmer, CA, USA) and an ABI automated DNA sequencer (Perkin Elmer, CA, USA).

Results

The peripheral blood mononuclear cells from 18 patients with early inflammatory arthritis and nine patients with established rheumatoid arthritis were stained with antibodies recognising HLA-DRB1*04, its variants *0401 and *0404, and the shared epitope itself. Genomic DNA was extracted from the same sample and typed using PCR and sequence specific oligohybridisation with DNA probes. The figure shows representative FACS profiles and corresponding HLA genotypes. Increased
fluorescence in the phycoerythrin channel (indicating positive staining) was usually obvious on inspection, but quadrants were carefully set on all samples, using the secondary antibody GAM-PE alone (negative control) and the Mab NFLD.M6, which recognises a non-polymorphic determinant on HLA-DR as a positive control, to estimate staining in the phycoerythrin channel. As shown in the table, the panel of Mab correctly recognised the relevant cell surface products encoded by the corresponding HLA genotypes in all but one of the patients with early inflammatory arthritis (patients 1-18). Patient 15 oligotyped as HLA-DRB1*0401/*0101, but failed to react with the *0401 antibody. Both the oligotyping and the FACS analysis were repeated on this patient and gave the same results. Sequencing of the second exon of the HLA-DRB1*04 allele using genomic DNA as the substrate confirmed a normal *0401 genotype in this patient. The results of antibody staining were equivalent to HLA-DR oligotyping in nine patients (patients 19-27) with established rheumatoid arthritis.
By FACS analysis, there was no cross reactivity of the NFLD.D2 Mab with alleles which might bear the QARAA epitope.

**Discussion**

Several recent studies have clearly established that HLA-DRB1 status contributes to the severity and outcome of rheumatoid arthritis, and is a useful prognostic marker in early disease. However, for a variety of reasons, HLA typing in rheumatoid arthritis has generally only been available in the research setting. Most tissue typing laboratories are necessarily preoccupied with typing for organ transplantation and it is doubtful that even limited HLA analysis would be routinely available for patients with early inflammatory arthritis. Ease of access and turnaround time from the laboratory are also important issues in clinical practice.

The present study was undertaken to evaluate the performance of a panel of Mab which recognise the HLA-DRB1 subtypes associated with rheumatoid arthritis. There was concordance between the results of FACS analysis of Mab stained PBMNCs and DNA oligotyping in 26/27 cases. The antibodies identified the shared epitope in 14/14 cases and the presence of the HLA-DRB1*04 molecule in 12/12 cases. All four HLA-DRB1*0404 positive patients were correctly identified. Five out of six *0404 positive patients were correctly identified. One patient genotyped as HLA-DRB1*0401, but failed to react with the *0401 Mab (NFLD.D11). A similar discrepancy between HLA-DRB1*0401 genotype and NFLD.D11 Mab reactivity has been encountered in one other patient, but would appear to be unusual (Marshall WH, personal communication). There are several possible explanations for this observation. All patients with established rheumatoid arthritis were correctly typed in spite of the long term use of disease modifying antirheumatic drugs (DMARD) and potential DMARD induced downregulation of HLA class II expression. NFLD.D11 reactivity has been shown to be critically influenced by the presence of bound peptide in the peptide binding site of the class II HLA molecule, although the peptides involved are unknown. Antibody binding in this system could be influenced by the nature of the peptides available for presentation. Our HLA-DRB1*0401/*0101 patient whose PBMNC failed to stain with NFLD.D11 may have a disorder of peptide processing or loading in the HLA class II pathway. However, the positive staining for *0101 would argue against a generalised peptide processing abnormality in this patient and might suggest reduced expression of the *0401 molecule itself. Variable transcription of HLA genes due to promoter polymorphisms has been described previously and is being further examined in our patient.

FACS analysis of Mab stained PBMCs is rapid and the results were usually available within a day of blood collection. Use of the antibodies and interpretation of results requires a FACS machine and a skilled operator, although both of these are now commonly available in routine pathology laboratories. A twofold increase in antibody staining due to DNA homozygosity (as occurred with patients 12 and 18 in our study) is not readily observable from the FACS profile and this is a relative disadvantage of the Mab method. A “double dose” of the rheumatoid arthritis associated susceptibility alleles is associated with more severe disease and is detected by DNA oligotyping. One possible use of the Mab method would therefore be to screen shared epitope positive patients in order to select those needing DNA oligotyping. However, compound heterozygosity (HLA-DRB1*0401/*0404) seems to carry the worst prognosis in rheumatoid arthritis and this phenotype is readily identifiable using NFLD.D11 and NFLD.D13. We correctly identified the one HLA-DRB1*0401/*0404 compound heterozygote (patient 19) in our study using the Mab panel.

Epidemiological studies using DNA oligotyping have established that several HLA class II DRB1 alleles, and in particular the shared epitope coded by these alleles, exert an important influence on the severity of rheumatoid arthritis. DNA oligotyping remains the gold standard for determining HLA status, but is not widely accessible and therefore has had limited impact on clinical management in diseases like rheumatoid arthritis. We believe simplified methods for detecting the shared epitope itself and rheumatoid arthritis associated HLA subtypes—such as the one outlined in this paper—will aid in the prompt identification of patients with early inflammatory arthritis who are at greater risk for severe rheumatoid disease.

---

**Results of FACS analysis with the HLA-DR Mabs compared with the genotype as determined by DNA oligotyping in 18 patients (1–18) with early inflammatory arthritis and in nine (19–27) with established rheumatoid arthritis**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>0401,7</td>
</tr>
<tr>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,10</td>
</tr>
<tr>
<td>3</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>3,0405</td>
</tr>
<tr>
<td>4</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>0403,0102</td>
</tr>
<tr>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7,13</td>
</tr>
<tr>
<td>6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,3</td>
</tr>
<tr>
<td>7</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>0404,2</td>
</tr>
<tr>
<td>8</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>3,11</td>
</tr>
<tr>
<td>9</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>0101,2</td>
</tr>
<tr>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,3</td>
</tr>
<tr>
<td>11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,2</td>
</tr>
<tr>
<td>12</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>0401,0401</td>
</tr>
<tr>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>07,0103</td>
</tr>
<tr>
<td>14</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,3</td>
</tr>
<tr>
<td>15</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>0401,0101</td>
</tr>
<tr>
<td>16</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,3</td>
</tr>
<tr>
<td>17</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,13</td>
</tr>
<tr>
<td>18</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>0401,0404</td>
</tr>
<tr>
<td>19</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>0401,0404</td>
</tr>
<tr>
<td>20</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>0401,0101</td>
</tr>
<tr>
<td>21</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>0101,0103</td>
</tr>
<tr>
<td>22</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>0404,8</td>
</tr>
<tr>
<td>23</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>0404,3</td>
</tr>
<tr>
<td>24</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>0408,0101</td>
</tr>
<tr>
<td>25</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,11</td>
</tr>
<tr>
<td>26</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,7</td>
</tr>
<tr>
<td>27</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,8</td>
</tr>
</tbody>
</table>
Monoclonal antibodies in rheumatoid arthritis

Royal Melbourne Hospital for excellent technical assistance and Peter McNair for help with sample collection. We gratefully acknowledge the support of the Reid Charitable Trusts and the Australian National Health and Medical Research Council.

Use of monoclonal antibodies to detect disease associated HLA-DRB1 alleles and the shared epitope in rheumatoid arthritis
Ian Wicks, Geoff McColl, Angela D'Amico, Loretta Dougherty and Brian Tait

Ann Rheum Dis 1997 56: 135-139
doi: 10.1136/ard.56.2.135

Updated information and services can be found at:
http://ard.bmj.com/content/56/2/135

These include:

References
This article cites 11 articles, 2 of which you can access for free at:
http://ard.bmj.com/content/56/2/135#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Connective tissue disease (4253)
Degenerative joint disease (4641)
Immunology (including allergy) (5144)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)
Genetics (968)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/